AbbVie Inc. (ABBV)
| Market Cap | 462.58B +19.9% |
| Revenue (ttm) | 64.39B +10.4% |
| Net Income | 6.27B +67.7% |
| EPS | 3.54 +68.5% |
| Shares Out | 1.77B |
| PE Ratio | 73.95 |
| Forward PE | 17.25 |
| Dividend | $6.92 (2.64%) |
| Ex-Dividend Date | Oct 15, 2026 |
| Volume | 4,512,421 |
| Open | 261.67 |
| Previous Close | 257.12 |
| Day's Range | 260.10 - 264.65 |
| 52-Week Range | 190.75 - 267.47 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 277.31 (+5.94%) |
| Earnings Date | Oct 30, 2026 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial StatementsAnalyst Summary
According to 31 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $277.31, which is an increase of 5.94% from the latest price.
News
Ipsen considers building production site in U.S., WSJ says
Ipsen is debating on building a production site in the U.S., with plans the next big plant built will manufacture either its Dysport drug, a rival to AbbVie’s (ABBV) Botox,…
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill., Sept. 10, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.
AbbVie's migraine treatment meets late-stage study goal
AbbVie said on Thursday its migraine treatment had met the main goal of a late-stage study testing it as a preventive treatment of menstrual migraine in adults.
AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine
AbbVie (ABBV) announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related peptide, or CGRP, receptor antagonist, for the preventive treatment o...
AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
Menstrual migraine is a recurrent, debilitating migraine pattern, with attacks occurring around or during the menstrual period, a predictable time of increased biological vulnerability2,4 Atogepant de...
AbbVie price target raised to $315 from $300 at HSBC
HSBC analyst Rajesh Kumar raised the firm’s price target on AbbVie (ABBV) to $315 from $300 and keeps a Buy rating on the shares. The firm adjusted targets in the…
AbbVie Transcript: Wells Fargo 21st Annual Healthcare Conference
Immunology assets SKYRIZI and RINVOQ are driving growth with new indications and strong data, while oncology and neuroscience pipelines advance with innovative therapies and strategic capital allocation. Key milestones include phase III progress in oncology and rapid expansion in immunology.
AbbVie price target raised to $282 from $276 at BofA
BofA raised the firm’s price target on AbbVie (ABBV) to $282 from $276 and keeps a Buy rating on the shares after updating the firm’s estimates to incorporate zumilokibart following…
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS
AbbVie (ABBV) announced positive topline results from the Phase 3 Cervino study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies, SAT,...
AbbVie's blood cancer drug meets late-stage trial goals
AbbVie said on Thursday its drug for a type of blood cancer has met the main goals of a late-stage trial.
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival, hazard ra...
AbbVie completes acquisition of Apogee for $135.11 per share in cash
AbbVie (ABBV) announced that it has completed its acquisition of Apogee Therapeutics (APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement,…
AbbVie Completes Acquisition of Apogee Therapeutics
Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart, is ...
AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026.
AbbVie’s Allergan expands SkinMedica’s portfolio with Barrier Calming Cream
Allergan Aesthetics, an AbbVie (ABBV) company, expands SkinMedica’s portfolio of regenerative skincare products with the launch of Barrier Calming Cream. “SkinMedica was a pioneer in regenerative skin...
SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings
In clinical testing, Barrier Calming Cream improved skin barrier support and reduced skin dryness by 30% after just two weeks 1 SkinMedica ® also introduces HA 5® Hydra Collagen Facial Mist for easy, ...
AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
NORTH CHICAGO, Ill., Aug. 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.
AbbVie submits Skyrizi application to the EMA
AbbVie (ABBV) announced that it has submitted an application to the European Medicines Agency, or EMA, seeking approval for Skyrizi for subcutaneous induction for the treatment of adult patients with…
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for in...
Emily Field: Large pharma companies are going to continue looking at biotech
Emily Field, Head of U.S. Biopharma Equity Research at Barclays, says biotech is gaining momentum as M&A returns, capital markets reopen and breakthroughs in cancer vaccines fuel investor interest.
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentation Additionally, new dat...
AbbVie price target raised to $303 from $298 at Piper Sandler
Piper Sandler raised the firm’s price target on AbbVie (ABBV) to $303 from $298 and keeps an Overweight rating on the shares. The firm notes monthly third-party prescription data for…
AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
Since its 2016 launch, hundreds of exceptional students pursuing higher education have received the scholarship Now a renewable award, students may earn the AbbVie Immunology Scholarship for up to fou...
AbbVie price target raised to $300 from $295 at Wells Fargo
Wells Fargo raised the firm’s price target on AbbVie (ABBV) to $300 from $295 and keeps an Overweight rating on the shares. The firm’s preview of the company’s second half…